IL6 and Hutchinson-Gilford progeria syndrome: We reasoned that tocilizumab treatment could be beneficial in HGPS by reducing IL6‐related progeroid features and tested this hypothesis in cultured HGPS fibroblasts, LmnaG609G/G609G mouse cells, and in vivo in LmnaG609G/G609G mice (Osorio et al., 2011, 2012; Zaghini et al., 2020).